There are still many large clinical studies ongoing with SGLT-2 inhibitors, including those evaluating effects on heart failure: EMPEROR-Reduced, EMPEROR-Preserved, Dapa-HF, DELIVER; those evaluating effects on diabetic nephropathy: Dapa-CKD, EMPA-KIDNEY; and those evaluating effects on hypertension: PREHYPD. Here, SLC5A2 is linked to diabetic kidney disease.